Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Leon Berard , Lyon, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Lyon
Treatments:ChemotherapyHospital:Leon Berard
Drugs:Journal:Link
Date:Aug 2003

Description:

Patients: This Phase II randomized study involved 54 patients with hormone refractory metastatic prostate cancer. Patients were divided into two groups: Group 1 with 26 patients and Group 2 with 28 patients. For patients in Group 1, the median age was 68 and the median PSA was 85. For patients in Group 2, the median age was 68 and the median PSA was 254.

Treatment: For patients in Group 2, the treatment consisted of the chemotherapy drugs oxaliplatin (eloxatin) and 5-fluorouracil (5-FU).

Toxicity: For patients in Group 2, grade 3-4 toxicities included anemia, neutropenia, thrombocytopenia, vomiting, stomatitis, asthenia, and neurosensory.

Results: For patients in Group 2 the median overall survival was 11.4 months.

Support: The study was supported by a grant from Sanofi-Synthelabo. This company manufactures oxaliplatin (eloxatin).

Correspondence: Dr. S. Mackenzie





Back